One of the two most awaited drugs for Roche, Ocrevus, has been approved by the FDA (the other one is haemophilia candidate ACE910). In clinical trials, Ocrevus has shown exceptionally compelling results in treating multiple sclerosis (MS) drug along with a sound side-effect profile.
29 Mar 2017
Ocrevus approved
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Ocrevus approved
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
29 Mar 2017 -
Author:
Kamla Singh -
Pages:
3
One of the two most awaited drugs for Roche, Ocrevus, has been approved by the FDA (the other one is haemophilia candidate ACE910). In clinical trials, Ocrevus has shown exceptionally compelling results in treating multiple sclerosis (MS) drug along with a sound side-effect profile.